Related Experiment Videos
Therapy options in cutaneous T-cell lymphoma
1Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, TX 77030-4095, USA.
Abstract:
The treatment of cutaneous T-cell lymphoma (CTCL) is continually evolving, as new and emerging drugs are added to the growing arsenal of CTCL therapy. The availability of newly approved investigational therapies, such as bexarotene, denileukin diftitox (DAB389- IL2), monoclonal antibodies and novel chemotherapeutic agents, adds complexity to decisions on the management and treatment of CTCL patients. In formulating a treatment plan, therapeutic options are best approached through consideration of overall clinical staging (stage IA-IVB) and skin staging (T1-T4), which affect prognosis and the characteristics of each individual patient's disease. This article will present and discuss the optimal therapeutic agents for all clinical stages of CTCL patients, based on currently available and investigational agents.
Insights
New therapies are expanding cutaneous T-cell lymphoma (CTCL) treatment options. This review discusses optimal therapeutic agents for all CTCL stages, considering patient and disease characteristics for personalized care.
Area of Science:
- Oncology
- Dermatology
Background:
- Cutaneous T-cell lymphoma (CTCL) treatment is rapidly advancing with new drug approvals.
- Managing CTCL involves complex decisions due to a growing number of therapeutic options.
Purpose of the Study:
- To present and discuss optimal therapeutic agents for all clinical stages of CTCL.
- To guide treatment planning based on clinical staging, skin staging, and individual patient disease characteristics.
Main Methods:
- Review of currently available and investigational agents for CTCL treatment.
- Consideration of clinical staging (IA-IVB) and skin staging (T1-T4) in treatment selection.
Main Results:
- The evolving landscape of CTCL therapy includes bexarotene, denileukin diftitox, monoclonal antibodies, and novel chemotherapeutics.
- Treatment decisions are influenced by disease stage and individual patient factors.
Conclusions:
- Optimal CTCL management requires a tailored approach integrating staging and patient-specific disease characteristics.
- Emerging therapies offer new possibilities for treating all stages of CTCL.